1. A composition that includes a delta PKC activator, alpha PKC inhibitor, a pharmaceutically acceptable carrier that does not include Ca and Mg cations. The composition of claim 1, wherein the delta PKC activator is at least one selected from the group consisting of insulin and an insulin analogue. The composition of claim 2, wherein the insulin analog is at least one selected from the group consisting of insulin lispro, insulin aspart, insulin glargine, visfatin and L-α-phosphatidylinositol-3,4,5-trisphosphate, dipalmitoyl- , heptaammonium salt. 4. The composition of claim 2, wherein the insulin is at least one selected from the group consisting of human insulin, bovine insulin and porcine insulin. The composition of claim 4, wherein the insulin is recombinantly expressed. The composition of claim 2, wherein the alpha-PKC inhibitor is a peptide comprising the amino acid sequence shown in SEQ ID NO: 1, which has a myristoylated amino acid residue at its amino terminus. The composition of claim 1, wherein the pharmaceutically acceptable carrier not including Ca and Mg cations is an aqueous carrier that includes 0.2 g / L KCl, 0.2 g / L anhydrous KHPO, 8 g / L NaCl and 1.15 g / l anhydrous NaHPO. 8. A composition that includes insulin, a peptide comprising the amino acid sequence shown in SEQ ID NO: 1, and has a myristylated amino acid residue at its amino terminus, and an aqueous pharmaceutically acceptable carrier comprising 0.2 g / l KCl, 0.2 g / l anhydrous KHPO, 8 g / l NaCl and 1.15 g / l anhydrous NaHPO, which does not include Ca and Mg cations. 9. The composition of claim 8, comprising from about 0.0001 units / L to about 0.1 units / L of insulin and from about 1 μM to about 100 μM peptides1. Композиция, которая включает дельта-PKC активатор, альфа-PKC ингибитор, фармацевтически приемлемый носитель, не включающий Caи Mgкатионы.2. Композиция по п.1, где дельта-PKC активатор является, по меньшей мере, одним, выбранным из группы, которая включает инсулин и анало
